Introduction
Ciliary neurotrophic factor (CNTF) was originally identified, and named, on the basis of its ability to promote the survival of parasympathetic motor neurons found in the embryonic chick ciliary ganglion (Adler et al., 1979; Lin et al., 1989; Stockli et al., 1989) . CNTF also acts on a variety of other embryonic neurons, including peripheral sensory neurons (Barbin et al., 1984) sympathetic neurons (Barbin et al., 1984; Ernsberger et al., 1989; Saadat et al., 1989) , hippocampal neurons (Ip et al., 1991) , preganglionic sympathetic neurons (Blottner et al., 1989) , and cranial and spinal motor neurons (Arakawa et al., 1990; Sendtner et al., 1990; Wewetzer et at., 1990; Oppenheim et al., 1991; Martinou et al., 1992; Vejsada et al., 1995) . Of all the actions of CNTF, those on motor neurons have attracted the most attention. In addition to its survival and differentiative effects on cultured embryonic motor neurons in vitro (Arakawa et al., 1990; Martinou et al., 1992) , exogenously provided CNTF can rescue motor neurons from ontogenetic cell death in the embryo (Wewetzer et al., 1990 ; Oppenheim et al., 1991) and can support motor neurons following axotomy in newborns (Sendtner et al., 1990; Vejsada et al., 1995) . Exogenously provided CNTF can also blunt progression in several mouse models of motor neuron disease (Sendtner et al., 1992a; Mitsumoto et al., 1994; Sagot et al., 1995) , raising the possibility that CNTF may be of therapeutic value for motor neuron diseases in humans. The ability of CNTF to maintain motor neurons led to consideration of CNTFas acandidate for the long sought-after nerve-or muscle-derived neurotrophic activity that seemingly regulates motor neuron survival in the embryo (Hamburger, 1975; Oppenheim, 1989; Wewetzer et al., 1990; Oppenheim et al., 1991) . This neurotrophic activity is thought to be present in limiting amounts during the developmental period when motor neurons contact their target and compete for neurotrophic support and thus apparently ensures survival of only those motor neurons making appropriate connections.
Despite the impressive effects of ectopically administered CNTF on embryonic and adult motor neurons, as well as on other neuronal populations, recent analyses of mice and humans containing mutated CNTF genes suggest that endogenous CNTF does not, in fact, play a critical role in the development of motor neurons or other neuronal populations. Mice homozygous for null mutations in the CNTFgene appear remarkably normal (Masu et al., 1993) . They are viable and initially thrive, and only later in adulthood do they exhibit a very mild loss of motor neurons with resulting minor muscle weakness. Even more astonishingly, a study of the Japanese population has revealed that a significant fraction, approximately 2.5%, are homozygous for mutations that inactivate the CNTFgene (Takahashi et al., 1994) . These individuals lacking CNTF are seemingly not adversely affected in any way and have not yet been shown to have any associated neurologic abnormalities.
Consistent with this genetic evidence that CNTF does not play a major role during development, it has been shown that CNTF is normally expressed only at very low levels in the embryo (Stockli et al., 1991; Ip et al., 1993) . Furthermore, CNTF lacks a signal peptide and is found stored inside of adult glial cells, perhaps awaiting release by some mechanism induced by injury (Sendtner et al., 1992b; Rende et al., 1992; Friedman et al., 1992) . These studies of CNTF expression, together with the findings that mice and humans lacking CNTF develop and mature quite normally, have led to the suggestion that CNTF is not essential during development or for life but instead acts in response to injury or other stresses.
CNTF is a member of a family of distantly related cytokines that includes leukemia inhibitory factor (LIF), interleukin-6(IL-6), interleukin-1 1 (IL-l l), oncostatin M (OSM), and cardiotrophin-1 (Bazan, 1991; Rose and Bruce, 1991; Pennica et al., 1995) . CNTF utilizes a three-component receptor system consisting of a CNTF-specific binding component, known as CNTFRa (Davis et al., 1991) , as well as two signal-transducing 8 receptor subunits, gpl36 and LlFRj3 (Taga et al., 1989; Hibi et al., 1990; Gearing et al., 1991) which it shares with its cytokine relatives (Ip et al., 1992; Gearing et al., 1992; Davis et al., 1993; Stahl et al., 1993; Stahl and Yancopoulos, 1993; Baumann et al., 1993; Stahl and Yancopoulos, 1994) . These three components are all initially unassociated on the cell surface, but form a complex in response to CNTF. The first step in complex formation involves the binding of CNTF to its a receptor component, followed by recruitment of the 6 components to form the complete complex; the 6 components do not bind to CNTF in the absence of CNTFRa (Ip et al., 1992; Davis et al., 1993) . Complex formation, in particular, 6 component dimerization, initiates the signaling process by activating cytoplasmic tyrosine kinases (members of the Jak/Tyk family) that are constitutively preassociated with the cytoplasmic domains of each of the 6 components (Stahl and Yancopoulos, 1993; Stahl et al., 1994; Lutticken et al., 1994; Stahl et al., 1995) . In contrast with the 6 components, CNTFRa lacks a cytoplasmic domain (it is linked to the surface via a glycosylphosphatidylinositol linkage) and plays no role in signaling (Davis et al., 1991; Stahl and Yancopoulos, 1994) . The sole function of CNTFRa seems to involve specificity determination;
i.e., since CNTF cannot bind to or activate its 6 components in the absence of CNTFRa, the expression of CNTFRa determines which cells can respond to CNTF (Ip et al., 1993; Stahl and Yancopoulos, 1994) . Thus, because the CNTFRa subunit is generally restricted to the nervous system in its expression, the actions of CNTF are largely limited to neurons and glia (Ip et al., 1993; Stahl and Yancopoulos, 1994) . It is this specific expression of CNTFRa that underlies the role of CNTF as a neurotrophic factor, and which distinguishes CNTF from its more generally acting cytokine relatives. Other members of the CNTF cytokine subfamily, such as IL-6 and IL-1 1, also have their own specificity-determining a components, which are widely expressed outside of the nervous system, for example in hematopoietic cells, explaining the more general actions of these cytokines (Kishimoto et al., 1992; Hilton et al., 1994) .
CNTFRa is expressed on all cells that are known to respond to exogenously provided CNTF and is also expressed on many additional embryonic and adult neuronal populations that have not yet been evaluated for their CNTF responsiveness (Ip et al., 1993) . The widespread expression of CNTFRa in the developing nervous system of the embryo is consistent with the observations that exogenously provided CNTF can act on many embryonic neurons, but seems perplexing if CNTFRa merely acts as a receptor for a factor that only acts later in life (Ip et al., 1993) . This apparent paradox has led to speculation that a ligand other than CNTF may also use CNTFRa and that this ligand might play a much more critical role during early development, and perhaps even in the adult, than does CNTF (Ip et al., 1993) . To explore this possibility, we have generated and compared mice containing null mutations in either the gene encoding CNTF or that encoding CNTFRa. In contrast with mice lacking CNTF, mice lacking CNTFRa die shortly after birth and exhibit profound deficits in all motor neuron populations examined. These mice provide compelling genetic evidence that CNTFRa does indeed play a critical role in the developing nervous system, most likely by serving as the receptor for a second, developmentally important, CNTF-like factor.
Results

Contrasting
Phenotypes
Result from CNTF and CNTFRa Genetic Mutations Replacement vectors were constructed and employed in positive-negative selection protocols, involving successive G418 and gancyclovir selections (Mansour et al., 1988) intended to disrupt either the CNTF or CNTFRa genes by homologous recombination in embryonic stem (ES) cells (Figures 1 and 2 and CNTFRa4-pups, using a rat CNTFRa cDNA probe. Indicated are CNTFRa precursor (small arrowhead), normal coding (arrow), and truncated transcripts (from the mutant allele; large arrowhead).
germline at high frequency. The Fl progeny heterozygous for either the CNTF mutation or the CNTfRa mutation were viable and appeared overtly normal and fertile and were bred to generate mice homozygous for either the null mutation in the CNTF gene (designated C/UP) or the null mutation in the CNTFRa gene (designated CNTFRa-I-) (Figures 28 and 38, respectively). Consistent with previous findings (Masu et al., 1993 ), mice we generated that were lacking CNTF were viable and exhibited no overt abnormalities. Conversely, in litters intended to generate mice homozygous for the null mutation in CNTFRa, approximately 25% (45 of 169) of the newborn pups did not feed, as evidenced by a lack of milk in their stomachs, and died during the first postnatal day (Figure 3 ). Genotyping by Southern blot analysis revealed that most of the pups exhibiting perinatal lethality (90 of 99 genotyped) were homozygous for the disrupted CNTFRa allele. In contrast, all of the surviving pups were either wild-type or heterozygous for this allele; not a single newborn mouse homozygous for the disrupted CNTFRa allele survived longer than 24 hr (Figure 38 ).
Like the CNTF-'-pups, the overt appearance of the CNTFRP mutant pups was normal aside from the lack of milk in their stomachs ( Figure 3A) , and their weights at birth did not significantly differ from those of their wild-type littermates. However, a behavioral analysis performed within the first 6-8 hr after birth revealed that the mice homozygous for the disrupted CNTFRa allele did not move their jaws as notably as feeding littermates, qualitatively assessed by their ability to open their mouths in response to a tail pinch and to vibrissal pin pricks. In addition, these mice were unable to suckle. The dramatic viability differences between mice lacking CNTFRa and CNTF are consistent with speculation that CNTFRa serves a critical role during development that does not involve CNTF, most likely by serving as a receptor for a second, developmentally important, CNTF-like ligand.
Mice Lacking CNTFRa Lack Responsiveness to CNTF, Confirming That CNTFRa Is a Required CNTF Receptor Component Before further analyzing the phenotype of the CNTFRa-Imice and comparing them with the CNTF-Imutant mice, we confirmed that the gene disruptions resulted in null mutations. lmmunoblot analysis for CNTF protein in the adult sciatic nerve revealed that while wild-type nerve ex- from CNTFRa+'+(n = 2) CNTFRa+J-(n = 3) and CNTFRa" (n = 3) mice. (6) LIF (50 nglml), but not CNTF (50 nglml), can induce tyrosine phosphorylation of their shared 6 subunits (LIFR6 and gp130) in brains isolated from CNTFRa-'+ mice; brains from CNTF-'-mice were used as control.
tracts contained abundant amounts of CNTF protein, CNTF was undetectable in nerve extracts of C/VT? mice (see Figure 1 C) . Similarly, Northern blot analysis of CNTFRa brain RNA levels revealed a novel truncated RNA species (large arrowhead) with reduced normal transcripts (arrow) in CNTFRa+'-mice, and complete absence of the normal CNTFRa transcripts in CNTFRa-'- mice (see Figure 2C ). To determine whether CNTFRa is the major in vivo receptor mediating CNTF responses, we tested whether neurons in the CNTfRa? mutant mice had lost the ability to respond to exogenously provided CNTF. Sensory neurons from the dorsal root ganglia (DRGs) of newborn CNTFRa-'-mutant mice and wild-type controls were isolated and cultured in the presence of CNTF, LIF, or nerve growth factor (NGF), which normally mediate in vitro survival of these neurons. As seen in Figure 4A , neurons cultured from the CNTFRa+ mice were comparable to their wild-type and CNTFRa+'-littermates in their responsiveness to both NGF and LIF, but differed in their responsiveness to CNTF. The complete lack of survival in the presence of CNTF demonstrates that for these peripheral sensory neurons, CNTFRa is a required CNTF receptor component, and that there is not an alternate CNTF receptor.
We then confirmed that CNTFRa is the major CNTF receptor not just for peripheral neurons but for those in the central nervous system as well. Membrane fractions were prepared from CNTFRa-I-newborn brains, as well as from CNTF- brains to serve as controls, and used to compare the ability of LIF and CNTF to induce tyrosine phosphorylation of their shared 6 subunits, gp130 and LIFRB. In the absence of added factor, there was a low basal level of 6 subunit phosphorylation in both the CNTFFk- and CNTF-'-brains (Figure 48, lanes 1 and 4) . Following the addition of LIF, the b subunit phosphorylation levels in both the CNTFRa+ and CNTF-I-samples increased as expected (lanes 3 and 6) . However, the addition of CNTF induced a phosphorylation increase in the CNTF-/-sample (lane 5) but not in the sample from CNTfRa-'-mice (lane 2). These observations demonstrate that, as was the case for peripheral sensory neurons, central nervous system neurons do not possess a major alternative CNTF receptor component that can be used by CNTF to activate its j3 subunits.
Motor Neuron Number Is Dramatically
Reduced in Brainstem Motor Nuclei and in the Spinal Cord of Mice Lacking CNTFRa but Not in Mice Lacking CNTF Because of the dramatic phenotypic differences between the mice lacking CNTFRa and those lacking CNTF, we decided to examine specific neuronal populations in which deficits could account for the phenotypic differences. Motor neuron populations were obvious candidates, since embryonic motor neurons are known to respond to CNTF but are reportedly not affected in young mice lacking CNTF, raising the possibility that the putative second ligand for CNTFRa could play a critical role in the normal development of these neurons. Because the motor neurons most likely to be involved in the feeding and suckling process would be found in brain stem motor neuron nuclei, we first counted neurons in the facial motor nucleus(FMN), trigeminal motor nucleus (TMN), and hypoglossal motor nucleus (HMN), which provide motor innervation to the face, jaw, and tongue musculature, respectively (Kandel et al., 1991) . Cell counts of these motor nuclei in newborn pups revealed that each exhibited significant losses in CNTfRa-I-mice as compared with littermate controls, amounting to reductions of 41% in the FMN, 27% in the TMN, and 51% in the HMN (Table 1 ; e.g., Figure 5A ); reductions were not seen in mice heterozygous for the CNTFRa mutation. As previously noted for the FMN in young mice lacking CNTF (Masu et al., 1993), we did not notice significant reductions in either the FMN or TMN in newborn mice lacking CNTF (Table 1) .
To determine whether the dramatic reduction in motor neuron number seen in mice lacking CNTFRa was restricted to brainstem motor nuclei or instead generally true of motor neuron populations, we quantitated motor neuron numbers in the lumbar region of the spinal cord. This motor neuron population exhibited about a 33% reduction in cell number in CNTFRaP mice as compared with wild-type littermate controls (Table 1; Figure 58 ). Furthermore, morphometric measurements showed that the cross-sectional area of spinal cord motor neurons of CNTFRa-'-mice was significantly reduced by 12% (P < 0.0001, according to has been previously noted that mice lacking CNTF do not exhibit an effect on spinal cord motor neurons until 8 weeks of age (Masu et al., 1993) .
The Effect of the CNTFRa Mutation on Sympathetic and Sensory Ganglia
The CNTFRa is expressed on sensory neurons in embry onic DRGs and trigeminal sensory ganglia (TGs), as well as on sympathetic neurons in the superior cervical ganglia (SCGs); CNTF is known to elicit survival and differentiative responses from DRG and SCG neurons. To begin to determine whether the putative second ligand for the CNTFRa might be as critical for the normal development of these neurons, as it appears to be for the normal development of motor neuron populations, we performed a preliminary histological analysis of these ganglia. Volumetric measurements revealed that the size of L5 DRGs, TGs, and SCGs were unaffected by the CNTFRa gene disruption (Table 2 ). Histological examination of these ganglia did not reveal substantial morphological differences in their neuronal populations in CNTFRa+ and control mice (e.g., Figure 58 , upper panels). More extensive analysis will be required to determine whether these ganglia are affected in a more subtle manner in CNTFRc- mice, prior to ruling out a role of the second ligand for CNTFRa on these neuronal populations.
Discussion
Evidence for a Second Ligand Using the CNTF Receptor The widespread expression of CNTFRa in the developing nervous system, together with the well-known survival and differentiative effects of CNTF on many different types of embryonic neurons, seemed to be at odds with findings that CNTF itself was not prominently expressed in the em- bryo, and that mice and humans lacking CNTF did not exhibit any notable problems with the development of their nervous systems. This apparent paradox led to speculation first that CNTFRa might bind a second CNTF-like ligand; second, that this alternative ligand might be much more critical during normal development than CNTF itself; and third, that the actions of exogenously provided CNTF on embryonic neurons might simply reflect the more physiologically relevant actions of this CNTF-like factor (Ip et al., 1993) . We now provide compelling genetic evidence supporting the notion that CNTFRa is indeed utilized by a ligand other than CNTF, that this factor is critical for normal development and postnatal viability, and that it is particularly required for the normal development of all motor neuron populations examined. This genetic evidence comes from the comparative analysis of mutant mice carrying either CNTFor CNTFRa gene disruptions. While mice lacking CNTF are viable, initially thrive, and only late in life develop a mild loss of motor neurons as previously described (Masu et al., 1993) , mice lacking CNTFRa are much more severely affected; they cannot feed, suffer from profound reductions in their motor neuron numbers, and die on the day of birth.
Until the putative second ligand for CNTFRa is identified, it cannot be excluded that the discrepancy in phenotypes between the CNTFRa-'-and CNTF-'-mice results from a ligand-independent role of CNTFRa that is critical for proper neuronal development. However, discrepancy between the phenotype resulting from the lack of a ligand as compared with the phenotype stemming from the lack of its cognate receptor has been seen in other systems. In all these cases, the discrepancy has been explained by the fact that the receptor does indeed prove to be utilized by multiple closely related ligands. For example, humans lacking interleukin-2 are mildly affected as compared with individuals mutant in the interleukin-2 y receptor component, who suffer from severe combined immunodeficiency, as this receptor component is also utilized by interleukin-4, interleukin-7, interleukin-13, and interleukin-15/T (Noguchi et al., 1993; Nowak, 1993) . Likewise, mice lacking the insulin-like growth factor I receptor (Liu et al., 1993) are more severely compromised than micelackinginsulin-likegrowthfactor I(Bakeretal., 1993), because this receptor is also utilized by the developmentally important insulin-like growth factor II (DeChiara et al., 1990) . Similarly, some neuronal populations are much more dramatically affected in mice lacking TrkB than in mice lacking brain-derived neurotrophic factor (BDNF) (Klein et al., 1993; Ernfors et al., 1994; Jones et al., 1994) presumably because TrkB serves as the in vivo receptor for other neurotrophins as well (Ip et al., 1993; Snider, 1994) . Supporting this notion, particular neuronal populations (i.e., nodose sensory neurons) are similarly reduced in mice lacking both BDNF and neurotrophin4, as they are in mice lacking TrkB (Conover et al., 1995) . Thus, CNTFRa resembles not only other growth factor receptors, but more specifically other neurotrophic factor receptors, in that it appears to be utilized by multiple ligands in vivo. Interestingly, CNTFRa is somewhat unusual as compared with these and other promiscuous receptor components, in that it functions solely as a specificitydetermining subunit, and not as a signal transducer, making it the first example of a specificity-determining subunit that is shared by multiple ligands. It remains to be determined whether the presumptive alternative ligand for CNTFRa utilizes the same signal-transducing 6 components as does CNTF.
Are any of the known members of the CNTF cytokine family likely candidates for the alternative ligand utilizing CNTFRa? Examination of available data argues that each of these ligands is an improbable choice. LIF, OSM, IL-6, and IL-11 neither require nor seem to bind CNTFRa in vitro (Stahl and Yancopoulos, 1994) ; the recently identified cardiotrophin 1 acts on cells that do not express CNTFRa and thus also does not appear to require this receptor component (Pennicaet al., 1995) . Furthermore, disruption of the genes for LIF or IL-6 does not yield phenotypes resembling that seen in mice lacking CNTFRa (Stewart et al., 1992; Escary et al., 1993; Kopf et al., 1994) . Growthpromotingactivity(GPA) isaCNTFrelative recently cloned from chicken (Leung et al., 1992 ). Because we have not been able to clone another CNTF homolog from chick following extensive PCR-based and low stringency homology cloning efforts (N. Y. I., P. Masiakowski, and G. D. Y., unpublished data), GPA appears to be the closest chicken counterpart to CNTF rather than a new family member. Thus, it seems that our genetic evidence points toward the existence of a heretofore undescribed CNTF relative that shares the CNTF specificity-determining component, CNTFRa; this ligand may share only limited homology with CNTF, on the basis of our inability to clone it via homologybased approaches. In addition to this novel and neurally acting CNTF-like relative, it is possible that other members of the CNTF/LIF/IL-6/lL-1 i/OSM/cardiotrophin 1 family, which do not bind CNTFRa, remain to be discovered. Recent analyses of mice lacking LlFRf3 reveal that they die at birth, as we have described for mice lacking CNTFRa, but also that they exhibit much more widespread problems, in the development of bone, glycogen metabolism, placenta, and glia, than we have observed in mice lacking CNTFRa (Ware et al., 1995;  T. D., C. S., C. Ware, and G. D. Y., unpublished data). Because these widespread abnormalities have also not been found in mice lacking LIF, it seems likely that LIFRP is shared in vivo not only by the LIF and CNTF receptor systems, but by yet another widely acting cytokine; OSM and cardiotrophin 1 may correspond to this cytokine.
Role of the Alternative
CNTFRa Ligand during Motor Neuron Development On the basis of our analysis, it remains unclear as to precisely why motor neuron numbers are reduced in the mice lacking CNTFRa. If the presumptive new ligand for CNTFRa acts as a classic target-derived neurotrophic factor during embryonic development, it may well be regulating survival of nascent motor neurons during the period of naturally occurring cell death that takes place just after these neurons contact their target, the developing muscle; for facial and lumbar cord motor neurons, this process is complete by late gestation in the mouse (Lance-Jones, 1982; Ashwell and Watson, 1983) . Alternatively, the new CNTFRa ligand may be involved in the generation of motor neurons, by modulating the proliferation or differentiation of precursors, and thus the lack of CNTFRa expression may result in reduced production of motor neurons; recent findings that CNTF can collaborate with other factors to promote the differentiation of neuronal precursors is consistent with this possibility (Ip et al., 1994) . Clearly, a detailed analysis of motor neuron development in embryos lacking CNTFRa is required to understand precisely the actions of the new CNTFRa ligand on these neurons.
Many neurotrophic agents have been shown to act on motor neurons in vitro or when artificially supplied in vivo. The physiological relevance of most of these agents for motor neuron development remains unclear. It had been reported that newborn mice lacking TrkB tyrosine kinase receptors displayed motor neuron deficits and consistently died within the first postnatal week (Klein et al., 1993) . More recently, and upon continuous breeding into a C57BU6 background, the TrkB-defective mice survive up to 3 weeks of age and do not display significant motor neuron deficits (I. Silos-Santiago and M. Barbacid, personal communication).
These observations resemble recent results obtained with mice lacking both BDNF and NT-4 (Conover et al., 1995; Liu et al., 1995) and suggest that signaling through TrkB receptors is not required for the generation of normal numbers of motor neurons during development. Analysis of mice disrupted for the CNTFRa gene appears to have defined a neurotrophic factor receptor system essential for normal motor neuron development in vivo. It should be noted, however, that substantial numbers of motor neurons, albeit somewhat atrophic, remain in newborn mice lacking CNTFRa. Therefore, it remains quite possible that motor neurons depend on additional classes of neurotrophic factors. It will be interesting to determine whether such ligands function independently or cooperatively with ligands using the CNTF receptor system, since collaborative and synergistic interactions between CNTF and other classes of factors have been demonstrated (e.g., Ip et al., 1994; Mitsumoto et al., 1994) . It also will be necessary to determine if such factors act on distinct motor neuron subpopulations.
Just as distinct motor neuron subsets can be defined on the basis of their target specificities and their patterns of LIM homeobox gene expression (Lewin, 1994; Tsuchida et al., 1994) , it may be found that different motor neuron subsets display distinct neurotrophic requirements in vivo; such subsets have been defined for sensory neuron populations in the dorsal root ganglia (Snider, 1994) or nodose ganglia (Conover et al., 1995 Figure IA) ; an Xhol-Sall 1.85 kb DNA fragment containing the MCI-thymidine kinase (f/q expression cassette was cloned into the unique Xhol site in this plasmid, and the resulting plasmid was digested with Spel to releasea 1.5 kb DNAfragment(containingcoding exons 1 and 2 of the CNTF gene) that was then replaced with the phosphoglycerate kinase (PGK)-neo expression cassette flanked with Xbal linkers to allow cloning into the compatible Spel site ( Figure 1A ). For the CNTFRa replacement vector, an 6 kb Hindlll-BamHI DNA fragment including exon 1 from the 5' end of the CNTFRa gene was cloned into pKS plasmid (Figure 2A) . A 1.8 kb Xhol-Hindlll DNA fragment containing the MCI-tk expression cassette was cloned into the unique Xhol-Hindlll sites of this plasmid, while a 1.8 kb Bglll DNA fragment containing the PGK-neo expression cassette was cloned into the unique BamHl site. A 3 kb Hindlll-Pstl DNA fragment from the 3' end of the CNTFRa gene, containing exons 8, 9, and 10, was blunt-ended, flanked with Xbal linkers, and cloned into the uniquexbal site to complete the targeting vector ( Figure 2A ). Both targeting vectors were linearized by digestion with Not1 and then electroporated into E14.1 ES cells, which were grown in 200 ug/ml G418 (GIBCO) and 2 uM gancyclovir; gancyclovir addition resulted in a 5-to lo-fold enrichment compared with selection in G418 alone. 
Phophorylation
Assays, Immunoblotting, and Northern Blotting To determine CNTF or LIF responsivity in newborn brains, the dissected Pl mouse brains were triturated on ice in 0.75 ml of PBS into a fine suspension.
Each sample was then equally divided and incubated with either control solution, CNTF (50 nglml), or LIF (50 nglml) for 15 min at room temperature with gentle agitation. Receptor complex activation was determined by LIFRP immunoprecipitation and phosphotyrosine immunoblotting as described (Stahl et al., 1993 (Stahl et al., , 1994 . For CNTF detection in sciatic nerves from adult CNTF-'-or CNlF+'+ mice, the nerves were homogenized in buffer containing 20 mM Tris (pH 7.6) 1 mM EDTA, 150 mM NaCI, 1 mM sodium orthovanadate, 10 pg/ml leupeptin, 10 Kg/ml aprotinin, and 1 mM PMSF and spun at 13,000 x g for 20 min. The supernatants were then concentrated with a Centriconconcentrator (Amicon) and quantified by using the BCA reagents (Pierce), and -200 ug of protein was loaded in each lane of a 12% polyacrylamide gel, which was then immunoblotted with the CNTF-specific polyclonal antibody RG0036. Northern blotting for CNTFRa RNA was performed as previously described (Ip et al., 1993) .
Motor Neuron Cell Counting and Morphometric Analysis Newborns were anesthetized and perfused with 3 ml of 0.9% NaCl containing 5 U/ml of heparin followed by3 ml of 4% paraformaldehyde in PBS (pH 7.4-7.6) and postfixed in 4% paraformaldehyde at 4OC. The brain and spinal cords were dissected out and cryoprotected by incubation in successive solutions of 17% and 30% sucrose in PBS at 4OC. Tissues were embedded in OCT compound (Miles Laboratory, Incorporated) and frozen at -58OC (spinal cord) or -30°C (brains) in isopentane cooled on dry ice. Cryostat serial sections of 20 urn (spinal cord) or 30 urn (brain) were mounted on gelatin-coated glass coverslips, air-dried, and stained with 0.1% cresyl violet. In some cases, the entire vertebral column including the cord was mounted in the coronal plane and sectioned.
Large cells in the ventral horns with abundant cytoplasm and a prominent nucleolus were counted on both sides; in the facial, trigeminal, and hypoglossal motor nuclei, large cells with a distinct nucleus were counted. Cross-section area of motor neurons was measured in sections 30 Km thick stained with cresyl violet, by using a PC-assisted image analysis system (Software Qwin of the Leica Quantimat 500). Only cell profiles containing a distinct nucleus with nucleolus were included. Spinal motor neurons were measured in the L4-L5 segments.
Volumetric Analyses of Peripheral Ganglia Ganglia were removed from perfused (DRGs and TGs) or nonperfused (SCGs) pups, postfixed as above, dehydrated in graded alcohols, and then paraffin-embedded.
Serial sections of 6 urn were cut and mounted on ProbeOn Plus slides (Fisher) and stained with cresyl violet. Each section was microscopically examined to identify all sections that contained neuronal somata. These sections were parcellated, from the beginning to the end of the ganglia, into 12 groups, and by using systematic random sampling methods, one section from each group waschosenforfurtheranalysis(PoverandCoggeshall,l99l).Analysis was performed on a digitized image of the section by using a computerassisted planimeter to measure the area occupied by neuronal cell bodies (Jandel Image Analysis Systems).
The volume of the ganglia, expressed in pm3, was calculated from the product of the average mean area (Km*) determined from the 12 sections, the section thickness (6 pm), and the total number of sections per ganglion.
